| 000 | 01528 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250518014519.0 | ||
| 264 | 0 | _c20190523 | |
| 008 | 201905s 0 0 eng d | ||
| 022 | _a1952-4013 | ||
| 024 | 7 |
_a10.1684/ejd.2018.3444 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStewart, Jacob R | |
| 245 | 0 | 0 |
_aAlemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review. _h[electronic resource] |
| 260 |
_bEuropean journal of dermatology : EJD _cDec 2018 |
||
| 300 |
_a764-774 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Systematic Review | ||
| 650 | 0 | 4 |
_aAlemtuzumab _xtherapeutic use |
| 650 | 0 | 4 |
_aAminopterin _xanalogs & derivatives |
| 650 | 0 | 4 |
_aAntimetabolites, Antineoplastic _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xtherapeutic use |
| 650 | 0 | 4 |
_aDeoxycytidine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aFolic Acid Antagonists _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMycosis Fungoides _xdrug therapy |
| 650 | 0 | 4 | _aRetreatment |
| 650 | 0 | 4 |
_aSezary Syndrome _xdrug therapy |
| 650 | 0 | 4 |
_aSkin Neoplasms _xdiagnostic imaging |
| 650 | 0 | 4 | _aGemcitabine |
| 700 | 1 | _aDesai, Neil | |
| 700 | 1 | _aRizvi, Syed | |
| 700 | 1 | _aZhu, Hong | |
| 700 | 1 | _aGoff, Heather W | |
| 773 | 0 |
_tEuropean journal of dermatology : EJD _gvol. 28 _gno. 6 _gp. 764-774 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1684/ejd.2018.3444 _zAvailable from publisher's website |
| 999 |
_c29203630 _d29203630 |
||